Role of Donor-Derived CD19.CAR-T Cells in Treating Patients That Relapsed after Allogeneic Hematopoietic Stem Cell Transplantation
Cheng Zhang(Naval Medical Research Command), Xi Zhang(Army Medical University), Xun Ye(Capital Medical University), Yingying Ma(Army Medical University), Ruihao Huang(Army Medical University), Defu Zeng(City Of Hope National Medical Center), Peiyan Kong(Army Medical University), Li Gao(Army Medical University), Jun Li(Capital Medical University), Jia Liu(Frederick National Laboratory for Cancer Research), Yao Liu(Chongqing University), Deping Han(Shanghai CASB Biotechnology (China)), Pengfei Jiang, Lei Gao(Zhejiang Chinese Medical University), Wei Cao(Academy of Military Medical Sciences), Wei-Ling Mei(Shanghai CASB Biotechnology (China)), Qinghui Xiong(Shanghai CASB Biotechnology (China))
Cited by 3
Related Papers
Recent advances in CAR-T cell engineering
|Journal of Hematology & Oncology|2020|403
Genomic and Transcriptomic Characterization of Natural Killer T Cell Lymphoma
|Cancer Cell|2020|234
TET2 Function in Hematopoietic Malignancies, Immune Regulation, and DNA Repair
|Frontiers in Oncology|2019|115
Bi-paratopic and multivalent VH domains block ACE2 binding and neutralize SARS-CoV-2
|Nature Chemical Biology|2020|114